Psychedelics

London, UK - 9 November 2020

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has joined the Psychiatry Consortium, an international collaboration to accelerate drug discovery and development in areas of urgent, unmet medical need.

The Psychiatry Consortium, managed by Medicines Discovery Catapult, is a strategic collaboration of leading medical research charities and pharmaceutical companies focusing on the challenge of identifying and validating novel drug targets to address the unmet therapeutic needs of people living with mental health conditions. COMPASS Pathways will work alongside Psychiatry Consortium members and academic partners to advance research projects, providing support through access to funding, expertise, and commercialisation know-how. The Psychiatry Consortium seeks project proposals from the global psychiatric research community via biannual open calls for applications - the next call for applications will open in January 2021.

Dr Gary Gilmour, Director of Preclinical Research, COMPASS Pathways, said, "The scale of today's mental health crisis is huge, and is getting bigger every day. The Psychiatry Consortium is bringing leading experts and resources together to speed up and reinvigorate the drug discovery process, and we are proud to be part of it. By working towards a common goal, we can bring evidence-based innovations to the people who need them, as quickly as possible."

About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. www.compasspathways.com

About the Psychiatry Consortium
The Psychiatry Consortium is a strategic collaboration of leading medical research charities and pharmaceutical companies focusing on the challenge of identifying and validating novel drug targets to address the unmet therapeutic needs of the people living with mental health conditions. The Psychiatry Consortium is managed by Medicines Discovery Catapult and supported by Wellcome. www.psychiatryconsortium.org

Forward-looking statements
This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding COMPASS's expectations of its future working relationship with Psychiatry Consortium. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the ability of Psychiatry Consortium to undertake or advance its research projects. Forward-looking statements contained in this announcement are made as of this date, and COMPASS undertakes no duty to update such information except as required under applicable law.

Enquiries:
Tracy Cheung, tracy@compasspathways.com , +44 7966 309024
Amy Lawrence, amy@compasspathways.com , +44 7813 777919

Westwicke (for investor enquiries)
Stephanie Carrington, stephanie.carrington@westwicke.com , +1 646-277-1282

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, has received permission from Health Canada to manufacture and distribute additional psychedelic substances, most notably MDMA, under the amended terms outlined in its June 20, 2022 application to Health Canada.

Under the leadership of Chief Science Officer Justin Kirkland, Optimi will now act as wholesale supplier of MDMA and other synthetic psychedelic compounds to approved researchers and drug developers.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
 Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

 Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

REVITALIST LIFESTYLE AND WELLNESS LTD. ("Revitalist" or the "Company") (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) announces it has signed a licensing partnership agreement with Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn') to implement their KARE® protocol for those suffering from Alcohol Use Disorder seeking sustained recovery measures focused on relapse prevention.

Awakn's proprietary ketamine-assisted therapy for the treatment of Alcohol Use Disorder was developed and validated in a Phase II a/b trial, with results announced in the American Journal of Psychiatry in January 2022. The trial delivered 86% abstinence over the six-month period post treatment versus 2% pre-trial and 25% in the current standard of care.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist

Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist

Awakn enters the U.S. addiction treatment and relapse prevention market

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) ("Revitalist"), one of the largest publicly listed U.S. based ketamine wellness-clinic chains. The agreement will enable Revitalist to treat clients with Awakn's proprietary ketamine-assisted therapy for the treatment of AUD.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd. ("iNGENū"), an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131.

Philip Young, CEO of Lobe Sciences stated, "We are extremely happy to have partnered with iNGENū as we move our proprietary stable psilocin products into human clinical trials. iNGENū is an industry leading, full service CRO providing end-to-end services for companies developing cannabinoid and psychedelic drugs. We evaluated CRO's in multiple geographies and chose iNGENu as their core values match ours and our commitment to discovering transformational therapies for multiple Central Nervous System diseases and trauma."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients

Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients

Blue Serenity brings science and compassion together, will cement Thomas Hartle's legacy as a Canadian psychedelic icon

Optimi and Hartle to host press conference today at 1:00 PM EST

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nirvana Life Sciences

Nirvana Appoints New Chief Financial Officer

Nirvana Life Sciences Inc., (CSE:NIRV) ("Nirvana" or the "Company") a Canadian based life sciences company aimed at developing non-addictive chronic pain and addiction treatment products announces that Connie Hang has resigned as Chief Financial Officer of the Company. The Company thanks Ms. Hang for her work as CFO over the last 2 years, she will continue serving the Company as a Contractor.

Annie Storey, CPA, CA, BBA has been appointed as Chief Financial Officer, effective immediately. Ms. Storey, a director of the Company since 2017, brings over 25 years' experience in accounting, auditing, financial reporting and corporate services for Canadian and US public companies in the mining, entertainment and biotechnology sectors.

Keep reading...Show less

Latest Press Releases

Related News

×